18.37

3.01% -0.57

After Hours: 18.37

Phathom Pharmaceuticals Inc (PHAT)

Overview News Price History Option Chain Financials Discussions Forecast

Phathom Pharmaceuticals Inc stock is traded at $18.37, with a volume of 505.28K. It is down -3.01% in the last 24 hours and up +6.49% over the past month. Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Previous Close:

$18.94

Open:

$18.98

24h Volume:

505.28K

Relative Volume:

0.54

Market Cap:

$1.26B

Revenue:

Net Income/Loss:

$-201.59M

P/E Ratio:

-4.1941

EPS:

-4.38

Net Cash Flow:

$-139.21M

1W Performance:

+6.31%

1M Performance:

+6.49%

6M Performance:

+82.97%

1Y Performance:

+110.42%

1-Day Range:

$17.90

$19.05

1-Week Range:

$16.76

$19.50

52-Week Range:

$6.065

$19.71

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Name

Phathom Pharmaceuticals Inc

Sector

Healthcare (1182)

Industry

Biotechnology (680)

Phone

(877) 742-8466

Address

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Employee

112

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

PHAT's Discussions on Twitter

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-09-23	Initiated	H.C. Wainwright	Buy
May-11-23	Upgrade	Evercore ISI	In-line → Outperform
Mar-13-23	Initiated	Craig Hallum	Buy
Oct-21-22	Initiated	Jefferies	Buy
May-06-22	Downgrade	Evercore ISI	Outperform → In-line
May-12-21	Upgrade	Goldman	Sell → Neutral
Feb-17-21	Initiated	BMO Capital Markets	Outperform
Feb-02-21	Initiated	Guggenheim	Buy
Jun-26-20	Downgrade	Goldman	Neutral → Sell
Nov-20-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Goldman	Neutral
Nov-19-19	Initiated	Jefferies	Buy
Nov-19-19	Initiated	Needham	Buy

View All

Phathom Pharmaceuticals Inc Stock (PHAT) Latest News

02:11 AM

Jennison Associates LLC's Strategic Acquisition in Phathom Pharm - GuruFocus.com

02:11 AM

Nov 04, 2024

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Nov 04, 2024

Nov 01, 2024

Investors bid Phathom Pharmaceuticals (NASDAQ:PHAT) up US$75m despite increasing losses YoY, taking one-year return to 96% - Yahoo Finance

Nov 01, 2024

Oct 31, 2024

Phathom Pharmaceuticals (PHAT) Scheduled to Post Quarterly Earnings on Thursday - MarketBeat

Oct 31, 2024

Oct 30, 2024

PHAT SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action InvestigationPHAT - Marketscreener.com

Oct 30, 2024

Oct 28, 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 - GlobeNewswire

Oct 28, 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business - The Bakersfield Californian

Oct 28, 2024

Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 - StockTitan

Oct 28, 2024

Oct 27, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the - GlobeNewswire

Oct 27, 2024

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - Yahoo Finance

Oct 27, 2024

Oct 23, 2024

Where are the Opportunities in (PHAT) - Stock Traders Daily

Oct 23, 2024

Oct 20, 2024

Shareholders have faith in loss-making Phathom Pharmaceuticals (NASDAQ:PHAT) as stock climbs 6.6% in past week, taking one-year gain to 74% - Simply Wall St

Oct 20, 2024

Oct 19, 2024

Creative Planning Has $278,000 Stock Position in Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) - Defense World

Oct 19, 2024

Oct 18, 2024

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Up 6.8%Time to Buy? - MarketBeat

Oct 18, 2024

Oct 17, 2024

Certain Common Stock of Phathom Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 18-OCT-2024. - Marketscreener.com

Oct 17, 2024

Oct 15, 2024